This inventor holds 1 USPTO granted patent. Top assignee: Adlai Nortye Biopharma Co., Ltd.. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Yongqiang Shi: Innovator in Immune-Related Disorders
Introduction
Yongqiang Shi is a notable inventor based in Zhejiang, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target immune-related disorders. His work is characterized by a commitment to advancing medical science and improving patient outcomes.
Latest Patents
Yongqiang Shi holds a patent for a PD-L1 antagonist compound. This patent includes a compound of Formula (I) and a pharmaceutical composition thereof. The method described in the patent is aimed at preventing and/or treating immune-related disorders, showcasing his innovative approach to addressing complex health issues.
Career Highlights
Yongqiang Shi is currently employed at Adlai Nortye Biopharma Co., Ltd. His role at the company allows him to leverage his expertise in drug development and contribute to groundbreaking research in the pharmaceutical industry. His dedication to innovation is evident in his work and the impact it has on healthcare.
Collaborations
Yongqiang has collaborated with esteemed colleagues such as Zhiyong Yu and Pan Li. These partnerships highlight the importance of teamwork in the pursuit of scientific advancements and the development of effective treatments.
Conclusion
Yongqiang Shi is a prominent figure in the field of pharmaceutical innovation, with a focus on immune-related disorders. His patent for a PD-L1 antagonist compound exemplifies his commitment to improving healthcare through scientific research. His contributions are paving the way for future advancements in medicine.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile